Evidence map›Paper›PMID 33586179›Full record

ArticleInternational journal of cancer2021

Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer center.

Jung Julie Kang, Vatche Tchekmedyian, Nader Mohammed, Alisa Rybkin, Sarin Kitpanit, Ming Fan, Huili Wang, Stephanie M Lobaugh, Zhigang Zhang, Anna Lee and 25 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 1 institution in 1 country.

Jung Julie KangDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-9773-5481
Vatche TchekmedyianDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Nader MohammedDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Alisa RybkinDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sarin KitpanitDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ming FanDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Huili WangDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Stephanie M LobaughDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Zhigang ZhangDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Anna LeeDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-9114-1815
Linda ChenDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Yao YuDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kaveh ZakeriDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Daphna Y GelblumDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Nadeem RiazDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sean M McBrideDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
C Jillian TsaiDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Marc A CohenDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jennifer R CracchioloDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Luc G MorrisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Bhuvanesh SinghDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Snehal PatelDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ian GanlyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-7636-5426
Jay O BoyleDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Richard J WongDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Juliana EngDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Wanqing Iris ZhiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-4263-7272
Kenneth NgDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Alan L HoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Lara A DunnDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Loren MichelDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
James V FettenDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
David G PfisterDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Nancy Y LeeDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Eric J ShermanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

High-dose (HD) cisplatin remains the standard of care with chemoradiation for locally advanced oropharyngeal cancer (OPC). Cooperative group trials mandate bolus-HD (100 mg/m

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsChemoradiotherapyCisplatinDrug Administration ScheduleFemaleFollow-Up StudiesHospitals, High-VolumeHumansMaleMiddle AgedNeoplasmsPrognosisRetrospective StudiesAntineoplastic AgentsCisplatin

Identifiers

PMID33586179
PMCPMC9380235
OpenAlexW3131893291

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.